Session Details

Session Details

03:45 PM - 05:30 PM - Ballroom 4

Amanda Gross - Auburn University

Co-Chair

03:45 PM - 05:30 PM - Ballroom 4

Russ Addis - NeuExcell Therapeutics

Co-Chair

03:45 PM - 04:00 PM - Ballroom 4

Anna Kabanova - NeuExcell Therapeutics

296: Neuron Regeneration Drives Functional Recovery from Severe Stroke Following Intracranial Administration of NXL-001 Gene Therapy in Non-Human Primates

04:00 PM - 04:15 PM - Ballroom 4

Ivana Trapani - Telethon Institute of Genetics and Medicine

297: AAV Intein Retinal Gene Therapy for Stargardt Disease is Effective and Safe in Large Animal Models

04:15 PM - 04:30 PM - Ballroom 4

Andrew Baik - Regeneron Pharmaceuticals

298: Tissue De-Targeting Abrogates Hepatotoxicity and Complement-Related Thrombotic Complications Associated with High-Dose AAV Gene Therapies

04:30 PM - 04:45 PM - Ballroom 4

Juliette Hordeaux - DVM, PhD. - University of Pennsylvania

299: Toxicity Profile of Clade F Vectors Administered Intravenously in Nonhuman Primates

04:45 PM - 05:00 PM - Ballroom 4

Shyam Ramachandran - PhD - Sanofi

300: AAV-ARSA Mediated Gene Replacement for the Treatment of Metachromatic Leukodystrophy

05:00 PM - 05:15 PM - Ballroom 4

Mugdha Deshpande - Dyno Therapeutics

301: Applying Artificial Intelligence to Multi-Property Optimization of AAV Capsids for Neuronal Gene Delivery

05:15 PM - 05:30 PM - Ballroom 4

Michael Kuipa - Emory National Primate Research Center

302: Improving the Expression of AAV-Delivered Anti-HIV Broadly Neutralizing Antibodies in Nonhuman Primates